Cyclophosphamide for graft vs host disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 4 registered trials.

Why this status

  1. 25 Sep 2025: Trial registered, NCT07193420
  2. 29 Sep 2026: Trial started, NCT07193420

The trials

NCT00492921: High-Dose Cyclophosphamide for Steroid Refractory GVHD

State
Completed
Phase
Phase 2
People
12 taking part
Started
May 2007
Primary completion
Jan 2013
Arms
Cyclophosphamide 50, Cyclophosphamide 100, Cyclophosphamide 150
Results
Posted on the registry
  1. 27 Jun 2007: Trial registered
  2. 14 Sep 2018: Trial results posted

NCT01749111: Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis

State
Stopped early
Phase
Phase 3
People
3 taking part
Started
Dec 2012
Primary completion
Aug 2016
Arms
Arm A
Results
None posted
  1. 13 Dec 2012: Trial registered

NCT07193420: Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies

State
Under way
Phase
Phase 3
People
180 planned
Started
29 Sep 2026
Primary completion
Sep 2030
Arms
Reduced dose
Results
None posted
  1. 25 Sep 2025: Trial registered
  2. 29 Sep 2026: Trial started

NCT07319000: Efficacy of Low-dose PT-Cy for Prevention of GVHD in Ambulatory Allogeneic HSCT

State
Completed
Phase
Phase 2
People
35 taking part
Started
1 Jan 2023
Primary completion
31 Dec 2023
Arms
Low-dose post-transplant cyclophosphamide
Results
None posted
  1. 1 Jan 2023: Trial started
  2. 31 Dec 2023: Trial completed
  3. 6 Jan 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as ARM A Cyclophosphamide, Cycloblastin, Cyclostin, Cytophosphan, Cytoxan, Cyclophosphamide 250 mg/m2; 3 days, Cyclophosphamide 35mg/kg/day, Cyclophosphamide 500 mg/m2; 2 doses, Cyclophosphamide 500 mg/m2; 3 doses, Cyclophosphamide 900 mg/m2; 1 day, Endoxan, Neosar, Procytox, Revimmune.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.